Abstract Number: PB0753
Meeting: ISTH 2021 Congress
Theme: Role of Hemostatic System in Cancer, Inflammation and Immunity » Platelets and Cancer
Background: Patients with hematological malignancies are at high risk of venous thromboembolism and bleeding that may have profound impact on treatment outcome and survival. As coagulopathy in hematological malignancies is a predictor of thrombotic and bleeding complications, by adding the intellectual observation of platelet count, we may segregate patients and identify the susceptibility to either thrombosis or bleeding apparently.
Aims: The study was designed to evaluate the significance of association of platelet count with prothrombin time (PT) and activated partial thromboplastin time (APTT) pre, during and post chemotherapy.
Methods: A retrospective cohort was studied at NIBD PECHS campus during 06 months period. Study population comprised of hematological malignant patients. PT, APTT and platelet count , pre, pro and post chemotherapy was assessed. Mann-Whitney U test and spearman correlation was applied to observe the association.
Results: A total of 52 cases were recruited, out of which 34 cases were analyzed based on inclusion criteria. Median age and range of patients was 30(13-68 years) with male predominance. Out of 34 cases, 14(41.2%) were on active chemotherapy, 11(32.4%) were post chemotherapy and in 9(26.5%) cases chemotherapy was not started. Overall PT and APTT was abnormal in 21(61.8%) and 24(70.6%) cases respectively. The association between platelet and count and PT and APTT is shown in table : 1 & 2. Spearman correlation revealed moderate negative correlation of platelet and APTT during chemotherapy and moderate negative correlation between platelet and PT before and post chemotherapy.
Conclusions: We concluded from this study that prolonged PT was associated with low platelet count and may be beneficial in taking diligent clinical decisions before starting chemotherapy. Additionally, risk of bleeding and thrombosis may be ruled out by comparing the platelet count with coagulopathy in patients undergo chemotherapy. This will not only improve treatment outcome but also lessen the unnecessary financial burden on patients.
To cite this abstract in AMA style:
Anwar N, Fatima N, Mujtaba H-, Shamsi T. Association of Platelet Count and Coagulopathy before, during and Post Chemotherapy: Is it Worth Doing? [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/association-of-platelet-count-and-coagulopathy-before-during-and-post-chemotherapy-is-it-worth-doing/. Accessed December 8, 2021.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/association-of-platelet-count-and-coagulopathy-before-during-and-post-chemotherapy-is-it-worth-doing/